252 related articles for article (PubMed ID: 33986332)
1. A predictive in vitro risk assessment platform for pro-arrhythmic toxicity using human 3D cardiac microtissues.
Kofron CM; Kim TY; Munarin F; Soepriatna AH; Kant RJ; Mende U; Choi BR; Coulombe KLK
Sci Rep; 2021 May; 11(1):10228. PubMed ID: 33986332
[TBL] [Abstract][Full Text] [Related]
2. Arrhythmia Assessment in Heterotypic Human Cardiac Myocyte-Fibroblast Microtissues.
Kofron CM; Choi BR; Coulombe KLK
Methods Mol Biol; 2022; 2485():147-157. PubMed ID: 35618904
[TBL] [Abstract][Full Text] [Related]
3. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
4. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
5. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
6. The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Hortigon-Vinagre MP; Zamora V; Burton FL; Smith GL
J Cardiovasc Pharmacol; 2021 Mar; 77(3):280-290. PubMed ID: 33109927
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
[TBL] [Abstract][Full Text] [Related]
8. Action potential metrics and automated data analysis pipeline for cardiotoxicity testing using optically mapped hiPSC-derived 3D cardiac microtissues.
Soepriatna AH; Navarrete-Welton A; Kim TY; Daley MC; Bronk P; Kofron CM; Mende U; Coulombe KLK; Choi BR
PLoS One; 2023; 18(2):e0280406. PubMed ID: 36745602
[TBL] [Abstract][Full Text] [Related]
9. The Use of Ratiometric Fluorescence Measurements of the Voltage Sensitive Dye Di-4-ANEPPS to Examine Action Potential Characteristics and Drug Effects on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Hortigon-Vinagre MP; Zamora V; Burton FL; Green J; Gintant GA; Smith GL
Toxicol Sci; 2016 Dec; 154(2):320-331. PubMed ID: 27621282
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Non-myocyte Cells Show Enhanced Pharmacological Function Suggestive of Contractile Maturity in Stem Cell Derived Cardiomyocyte Microtissues.
Ravenscroft SM; Pointon A; Williams AW; Cross MJ; Sidaway JE
Toxicol Sci; 2016 Jul; 152(1):99-112. PubMed ID: 27125969
[TBL] [Abstract][Full Text] [Related]
11. A 3-D human model of complex cardiac arrhythmias.
Williams K; Liang T; Massé S; Khan S; Hatkar R; Keller G; Nanthakumar K; Nunes SS
Acta Biomater; 2021 Sep; 132():149-161. PubMed ID: 33713861
[TBL] [Abstract][Full Text] [Related]
12. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
[TBL] [Abstract][Full Text] [Related]
13. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
[TBL] [Abstract][Full Text] [Related]
14. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
[TBL] [Abstract][Full Text] [Related]
15. Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone.
Shi M; Bouwmeester H; Rietjens IMCM; Strikwold M
Arch Toxicol; 2020 Aug; 94(8):2809-2827. PubMed ID: 32367273
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
Takasuna K; Kazusa K; Hayakawa T
Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
[TBL] [Abstract][Full Text] [Related]
17. Improving reliability and reducing costs of cardiotoxicity assessments using laser-induced cell poration on microelectrode arrays.
Iachetta G; Colistra N; Melle G; Deleye L; Tantussi F; De Angelis F; Dipalo M
Toxicol Appl Pharmacol; 2021 May; 418():115480. PubMed ID: 33689843
[TBL] [Abstract][Full Text] [Related]
18. Cardiac safety assessment with motion field imaging analysis of human iPS cell-derived cardiomyocytes is improved by an integrated evaluation with cardiac ion channel profiling.
Isobe T; Honda M; Komatsu R; Tabo M
J Toxicol Sci; 2019; 44(12):859-870. PubMed ID: 31813905
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
20. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
